Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q1 2022 vs. Q4 2021
How the institutions holding Damora Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 26 | 25 | −1 |
| Shares | 10.1M | 9.57M | −491.6K (−4.9%) |
| Value | $30.5M | $21.0M | −$9.43M (−30.9%) |
New holders (2)
Institutions that held Damora Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| JPMorgan Chase & Co | 1,766 | $4.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 406 | $1.00K | 0.00% |
Sold out (3)
Institutions that held Damora Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Anson Funds Management LP | 183,530 | $556.0K |
| Susquehanna International Group, LLP | 15,964 | $48.0K |
| Migdal Insurance & Financial Holdings Ltd. | 3,119 | $10.0K |